Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

INFLAMMATION

Human disease mutations highlight the inhibitory function of TIM-3

A new study identifies loss-of-function mutations in HAVCR2, which encodes TIM-3, in patients with a rare cutaneous T cell lymphoma associated with aberrant immunological activation. These mutations lead to loss of the TIM-3 immunological checkpoint, thus promoting inflammation and malignancy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: TIM-3 deficiency leads to uncontrolled immunological activation resulting in T cell malignancy and autoinflammation.

References

  1. Gayden, T. et al. Nat. Genet. https://doi.org/10.1038/s41588-018-0251-4 (2018).

    Article  PubMed  Google Scholar 

  2. Monney, L. et al. Nature 415, 536–541 (2002).

    Article  CAS  Google Scholar 

  3. Sabatos, C. A. et al. Nat. Immunol. 4, 1102–1110 (2003).

    Article  CAS  Google Scholar 

  4. Chiba, S. et al. Nat. Immunol. 13, 832–842 (2012).

    Article  CAS  Google Scholar 

  5. Fourcade, J. et al. J. Exp. Med. 207, 2175–2186 (2010).

    Article  CAS  Google Scholar 

  6. Jin, H. T. et al. Proc. Natl. Acad. Sci. USA 107, 14733–14738 (2010).

    Article  CAS  Google Scholar 

  7. Yan, J. et al. PLoS One 8, e58006 (2013).

    Article  CAS  Google Scholar 

  8. Sakuishi, K. et al. OncoImmunology 2, e23849 (2013).

    Article  Google Scholar 

  9. Dardalhon, V. et al. J. Immunol. 185, 1383–1392 (2010).

    Article  CAS  Google Scholar 

  10. Avery, L., Filderman, J., Szymczak-Workman, A. L. & Kane, L. P. Proc. Natl. Acad. Sci. USA 115, 2455–2460 (2018).

    Article  CAS  Google Scholar 

  11. Nakayama, M. et al. Blood 113, 3821–3830 (2009).

    Article  CAS  Google Scholar 

  12. Huang, Y. H. et al. Nature 536, 359 (2016).

    Article  CAS  Google Scholar 

  13. Zhu, C. et al. Nat. Immunol. 6, 1245–1252 (2005).

    Article  CAS  Google Scholar 

  14. Leitner, J. et al. PLoS Pathog. 9, e1003253 (2013).

    Article  CAS  Google Scholar 

  15. Hughes, R. C. Biochim. Biophys. Acta 1473, 172–185 (1999).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vijay K. Kuchroo.

Ethics declarations

Competing interests

V.K.K. has patents dealing with intellectual property that have been licensed to Novartis Pharmaceuticals by the Brigham and Women’s Hospital.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dixon, K.O., Das, M. & Kuchroo, V.K. Human disease mutations highlight the inhibitory function of TIM-3. Nat Genet 50, 1640–1641 (2018). https://doi.org/10.1038/s41588-018-0289-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41588-018-0289-3

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer